T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of suchtherapies.T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.

Biotechnology

T-Cypher Bio

Thomas L. Andresen

Sarah Leonard

Nathaniel Davies

Mark Lees

Hemza Ghadbane

The Leadership Team at T-Cypher Bio drives the strategic vision and operational execution of the company's mission to revolutionize TCR-based therapeutics. Comprising experts in scientific research, corporate development, and pre-clinical development, the team collaborates to advance the D-Cypher platform, foster innovation, and navigate the challenges of developing targeted therapies for solid tumors and other diseases. They ensure alignment across functional areas and guide the company's growth in the competitive biotechnology landscape.

��

Leadership Team

About

Team members

Other teams at T-Cypher Bio

Research and Development

��������

Leadership Team

About

Team members

Other teams at T-Cypher Bio

Research and Development

��